Publications
2023
Examining the effects of cytidine deaminase in pancreatic ductal adenocarcinoma cell lines and relation to gemcitabine and capecitabine efficacy
Rowley, W., Hale, J., Jackson, R., Costello-Goldring, E., Palmer, D., & Greenhalf, W. (2023). Examining the effects of cytidine deaminase in pancreatic ductal adenocarcinoma cell lines and relation to gemcitabine and capecitabine efficacy. Pancreatology, 23, e139-e140. doi:10.1016/j.pan.2023.06.758
Where the metabolome meets the microbiome for pancreatic cancer detection.
Oldfield, L., & Costello, E. (2023). Where the metabolome meets the microbiome for pancreatic cancer detection.. Cell reports. Medicine, 4(9), 101011. doi:10.1016/j.xcrm.2023.101011
Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians.
Piccardi, M., Gentiluomo, M., Bertoncini, S., Pezzilli, R., Erőss, B., Bunduc, S., . . . Campa, D. (2023). Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians.. Biological research, 56(1), 46. doi:10.1186/s40659-023-00457-y
Analysis of serum microRNA-122 in a randomized controlled trial of N-acetylcysteine for treatment of antituberculosis drug-induced liver injury
Moosa, M. S., Russomanno, G., Dorfman, J. R., Gunter, H., Patel, C., Costello, E., . . . Cohen, K. (2023). Analysis of serum microRNA-122 in a randomized controlled trial of N-acetylcysteine for treatment of antituberculosis drug-induced liver injury. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. doi:10.1111/bcp.15661
Chairwomen: Diagnostic studies for pancreatic cancer
Chelala, C., & Costello-Goldring, E. (2023). Chairwomen: Diagnostic studies for pancreatic cancer. Pancreatology, 23(4), e2. doi:10.1016/j.pan.2023.04.011
The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer
Campa, D., Gentiluomo, M., Stein, A., Aoki, M. N., Oliverius, M., Vodickova, L., . . . Canzian, F. (2023). The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 186. doi:10.1016/j.critrevonc.2023.104020
Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways
Quinn, L. M., Haldenby, S., Antzcak, P., Fowler, A., Bullock, K., Kenny, J., . . . Goldring, C. (n.d.). Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways. Scientific Reports, 13(1). doi:10.1038/s41598-023-33096-0
Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation
Ferguson, R., Aughton, K., Evans, A., Shaw, V., Armstrong, J., Ware, A., . . . Greenhalf, W. (2023). Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation. CURRENT ISSUES IN MOLECULAR BIOLOGY, 45(3), 2505-2520. doi:10.3390/cimb45030164
GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma
de Andres, M. P., Jackson, R. J., Felipe, I., Zagorac, S., Pilarsky, C., Schlitter, A. M., . . . Real, F. X. (2023). GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. GUT, 72(3), 535-548. doi:10.1136/gutjnl-2021-325803
The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis
Barrera, L. N., Ridley, P. M., Bermejo-Rodriguez, C., Costello, E., & Perez-Mancera, P. A. (2023). The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis. JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY, 79(1), 193-204. doi:10.1007/s13105-022-00899-0
2022
Genetically Determined Telomere Length Is Associated with Pancreatic Neuroendocrine Neoplasms Onset.
Gentiluomo, M., Capurso, G., Morelli, L., Ermini, S., Pasquali, C., Latiano, A., . . . Campa, D. (2022). Genetically Determined Telomere Length Is Associated with Pancreatic Neuroendocrine Neoplasms Onset.. Neuroendocrinology, 112(12), 1168-1176. doi:10.1159/000524659
The Effect of Sampling Methodology upon Pancreatic Cancer Microbiome Communities
Hale, J., Evans, A., Lilley, A., Fine, D., Costello-Goldring, E., Halloran, C., . . . Greenhalf, W. (2022). The Effect of Sampling Methodology upon Pancreatic Cancer Microbiome Communities. Pancreatology, 22, e61. doi:10.1016/j.pan.2022.06.157
United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer
Oldfield, L., Stott, M., Hanson, R., Jackson, R. J., Reynolds, W., Chandran-Gorner, V., . . . Costello, E. (2022). United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer. BMJ OPEN, 12(10). doi:10.1136/bmjopen-2022-068010
Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes
Oldfield, L., Evans, A., Rao, R. G., Jenkinson, C., Purewal, T., Psarelli, E. E., . . . Costello, E. (2022). Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. EBIOMEDICINE, 75. doi:10.1016/j.ebiom.2021.103802
2021
Early detection of pancreatic ductal adenocarcinomas with an ensemble learning model based on a panel of protein serum biomarkers
Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs
Brumskill, S., Barrera, L. N., Calcraft, P., Phillips, C., & Costello, E. (2021). Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs. JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY. doi:10.1007/s13105-021-00857-2
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
Aughton, K., Elander, N. O., Evans, A., Jackson, R., Campbell, F., Costello, E., . . . Greenhalf, W. (2021). hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. CANCERS, 13(22). doi:10.3390/cancers13225758
Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study
Rosato, V., Gomez-Rubio, P., Molina-Montes, E., Marquez, M., Lohr, M., O'Rorke, M., . . . Investigators, P. S. (2021). Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. EUROPEAN JOURNAL OF CANCER PREVENTION, 30(6), 423-430. doi:10.1097/CEJ.0000000000000588
Genetic polymorphisms involved in mitochondrial metabolism and pancreatic cancer risk.
Peduzzi, G., Gentiluomo, M., Tavano, F., Arcidiacono, P. G., Ermini, S., Vodicka, P., . . . Campa, D. (2021). Genetic polymorphisms involved in mitochondrial metabolism and pancreatic cancer risk.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. doi:10.1158/1055-9965.epi-21-0353
Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk
Lu, Y., Corradi, C., Gentiluomo, M., Lopez de Maturana, E., Theodoropoulos, G. E., Roth, S., . . . Canzian, F. (2021). Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. FRONTIERS IN GENETICS, 12. doi:10.3389/fgene.2021.693933
Abstract 1193: Digital quantification of GATA6 expression from immunohistochemistry is associated with overall survival after surgery for pancreatic cancer in the ESPAC trials
Grant, R. C., Duan, K., Jackson, R., Greenhalf, W., Costello-Goldring, E., Ghaneh, P., . . . Fischer, S. (2021). Abstract 1193: Digital quantification of GATA6 expression from immunohistochemistry is associated with overall survival after surgery for pancreatic cancer in the ESPAC trials. Cancer Research, 81(13_Supplement), 1193. doi:10.1158/1538-7445.am2021-1193
Association of genetic variants affecting microRNAs and pancreatic cancer risk
Lu, Y., Corradi, C., Gentiluomo, M., Theodoropoulos, G. E., Roth, S., Maiello, E., . . . Canzian, F. (2021). Association of genetic variants affecting microRNAs and pancreatic cancer risk. Pancreatology, 21, S60-S62. doi:10.1016/j.pan.2021.05.162
New‐onset Diabetes as a Harbinger of Pancreatic Cancer: is Early Diagnosis Possible?
Andersen, D. K., Chari, S. T., Costello, E., Crnogorac‐Jurcevic, T., Hart, P. A., Maitra, A., & Pandol, S. J. (2021). New‐onset Diabetes as a Harbinger of Pancreatic Cancer: is Early Diagnosis Possible?. In Unknown Book (pp. 409-417). Wiley. doi:10.1002/9781119570097.ch51
Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction
Galeotti, A. A., Gentiluomo, M., Rizzato, C., Obazee, O., Neoptolemos, J. P., Pasquali, C., . . . Campa, D. (2021). Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. JOURNAL OF MEDICAL GENETICS, 58(6), 369-377. doi:10.1136/jmedgenet-2020-106961
Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival.
Gentiluomo, M., Corradi, C., Vanella, G., Johansen, A. Z., Strobel, O., Szentesi, A., . . . Capurso, G. (2021). Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival.. Scientific reports, 11(1), 7570. doi:10.1038/s41598-021-87130-0
The holding temperature of blood during a delay to processing can affect serum and plasma protein measurements
Ashworth, M., Small, B., Oldfield, L., Evans, A., Greenhalf, W., Halloran, C., & Costello, E. (2021). The holding temperature of blood during a delay to processing can affect serum and plasma protein measurements. SCIENTIFIC REPORTS, 11(1). doi:10.1038/s41598-021-85052-5
A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer
Lopez de Maturana, E., Rodriguez, J. A., Alonso, L., Lao, O., Molina-Montes, E., Martin-Antoniano, I. A., . . . Malats, N. (2021). A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. GENOME MEDICINE, 13(1). doi:10.1186/s13073-020-00816-4
Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses
Molina-Montes, E., Coscia, C., Gomez-Rubio, P., Fernandez, A., Boenink, R., Rava, M., . . . Malats, N. (2021). Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. GUT, 70(2), 319-329. doi:10.1136/gutjnl-2019-319990
URINARY VOLATILE ORGANIC COMPOUNDS AS A BIOMARKER FOR PANCREATIC CANCER
Baker, J., Aggarwal, P., Chapman, E., Costello-Goldring, E., Greenhalf, B., & Probert, C. (2021). URINARY VOLATILE ORGANIC COMPOUNDS AS A BIOMARKER FOR PANCREATIC CANCER. In GUT Vol. 70 (pp. A172-A173). doi:10.1136/gutjnl-2020-bsgcampus.326
2020
A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study
Debernardi, S., O'Brien, H., Algahmdi, A. S., Malats, N., Stewart, G. D., Pljesa-Ercegovac, M., . . . Crnogorac-Jurcevic, T. (2020). A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. PLOS MEDICINE, 17(12). doi:10.1371/journal.pmed.1003489
GATA6 expression is prognostic after surgical resection of pancreatic cancer: results from the ESPAC trials
Grant, R. C., Duan, K., Jackson, R., Greenhalf, W., Costello-Goldring, E., Ghaneh, P., . . . Fischer, S. (2020). GATA6 expression is prognostic after surgical resection of pancreatic cancer: results from the ESPAC trials. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.PANCA20-PO-005
Pancreatic cancer biomarker from urinary volatile organic compounds
Aggarwal, P., Baker, J., Chapman, E., Greenhalf, B., Costello-Goldring, E., & Probert, C. (2020). Pancreatic cancer biomarker from urinary volatile organic compounds. Pancreatology, 20, S166-S167. doi:10.1016/j.pan.2020.07.319
The holding temperature of blood during a delay to processing can affect serum and plasma protein concentrations.
Small, B., Ashworth, M., Oldfield, L., Greenhalf, W., Halloran, C., & Costello-Goldring, E. (2020). The holding temperature of blood during a delay to processing can affect serum and plasma protein concentrations.. Pancreatology, 20, S120. doi:10.1016/j.pan.2020.07.217
Early detection of pancreatic cancer
Pereira, S. P., Oldfield, L., Ney, A., Hart, P. A., Keane, M. G., Pandol, S. J., . . . Costello, E. (2020). Early detection of pancreatic cancer. The Lancet Gastroenterology and Hepatology, 5(7), 698-710. doi:10.1016/S2468-1253(19)30416-9
Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties.
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2020). Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties.. Cancer Research, 80(13), 2861-2873. doi:10.1158/0008-5472.can-19-3534
Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships
Molina-Montes, E., Van Hoogstraten, L., Gomez-Rubio, P., Lohr, M., Sharp, L., Molero, X., . . . Malats, N. (2020). Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 29(5), 1009-1018. doi:10.1158/1055-9965.EPI-19-1027
Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer
Mahajan, U. M., Goni, E., Langhoff, E., Li, Q., Costello, E., Greenhalf, W., . . . Mayerle, J. (2020). Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. JNCI CANCER SPECTRUM, 4(1). doi:10.1093/jncics/pkz060
2019
Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches
Gomez-Rubio, P., Pinero, J., Molina-Montes, E., Gutierrez-Sacristan, A., Marquez, M., Rava, M., . . . Investigators, P. S. (2019). Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. INTERNATIONAL JOURNAL OF CANCER, 144(7), 1540-1549. doi:10.1002/ijc.31866
Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.
Evans, J. P., Winiarski, B. K., Sutton, P. A., Jones, R. P., Ressel, L., Duckworth, C. A., . . . Kitteringham, N. R. (2019). Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.. Oncotarget, 10(6), 685. doi:10.18632/oncotarget.26625
Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients.
Gentiluomo, M., Puchalt García, P., Galeotti, A. A., Talar-Wojnarowska, R., Tjaden, C., Tavano, F., . . . Campa, D. (2019). Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients.. Carcinogenesis, 40(4), 544-550. doi:10.1093/carcin/bgz006
Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer.
Sheel, A. R. G., Harrison, S., Sarantitis, I., Nicholson, J. A., Hanna, T., Grocock, C., . . . Greenhalf, W. (2019). Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer.. The American Journal of Gastroenterology (Elsevier), 114(1), 155-164. doi:10.1038/s41395-018-0395-y
2018
S100A8 and S100A9 proteins form part of a paracrine feedback loop between pancreatic cancer cells and monocytes
Nedjadi, T., Evans, A., Sheikh, A., Barerra, L., Al-Ghamdi, S., Oldfield, L., . . . Costello, E. (2018). S100A8 and S100A9 proteins form part of a paracrine feedback loop between pancreatic cancer cells and monocytes. BMC CANCER, 18. doi:10.1186/s12885-018-5161-4
Immune Cell and Stromal Signature Associated with Progression-free Survival of Patients with Resected Pancreatic Ductal Adenocarcinoma
Mahajan, U. M., Langhoff, E., Goni, E., Costello, E., Greenhalf, W., Halloran, C. M., . . . Mayerle, J. (2018). Immune Cell and Stromal Signature Associated with Progression-free Survival of Patients with Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology, 155(05), 1625-1639.E2. doi:10.1053/j.gastro.2018.08.009
Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker.
Martinez-Bosch, N., Barranco, L. E., Orozco, C. A., Moreno, M., Visa, L., Iglesias, M., . . . Navarro, P. (2018). Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker.. Oncotarget, 9(68), 32984-32996. doi:10.18632/oncotarget.26034
F<sub>1</sub>F<sub>0</sub>-ATP Synthase Inhibitory Factor 1 in the Normal Pancreas and in Pancreatic Ductal Adenocarcinoma: Effects on Bioenergetics, Invasion and Proliferation
Tanton, H., Voronina, S., Evans, A., Armstrong, J., Sutton, R., Criddle, D. N., . . . Tepikin, A. V. (2018). F<sub>1</sub>F<sub>0</sub>-ATP Synthase Inhibitory Factor 1 in the Normal Pancreas and in Pancreatic Ductal Adenocarcinoma: Effects on Bioenergetics, Invasion and Proliferation. FRONTIERS IN PHYSIOLOGY, 9. doi:10.3389/fphys.2018.00833
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
Evans, J. P., Winiarski, B. K., Sutton, P. A., Jones, R. P., Ressel, L., Duckworth, C. A., . . . Kitteringham, N. R. (2018). The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. Oncotarget, 9(43), 27104-27116. doi:10.18632/oncotarget.25497
The SPINK1 p.N34S variant is associated with early onset idiopathic recurrent acute pancreatitis progressing to chronic disease, but not with more rapid progression to other disease outcomes such as diabetes mellitus
Sarantitis, I., Sheel, A., Nicholson, J., McCarthy, E., Howard, E., Baron, R., . . . Greenhalf, W. (2018). The SPINK1 p.N34S variant is associated with early onset idiopathic recurrent acute pancreatitis progressing to chronic disease, but not with more rapid progression to other disease outcomes such as diabetes mellitus. Pancreatology, 18(4), S174-S175. doi:10.1016/j.pan.2018.05.471
Therapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018). Therapeutic developments in pancreatic cancer: current and future perspectives. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 15(6), 333-348. doi:10.1038/s41575-018-0005-x
The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.
Abbruzzese, J. L., Andersen, D. K., Borrebaeck, C. A. K., Chari, S. T., Costello, E., Cruz-Monserrate, Z., . . . Powers, A. C. (2018). The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.. In Pancreas Vol. 47 (pp. 516-525). doi:10.1097/mpa.0000000000001037
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy
Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., . . . Canc, E. S. G. P. (2018). Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 118, 1084-1088. doi:10.1038/s41416-018-0005-1
Development of Novel Diagnostic Pancreatic Tumor Biomarkers
Oldfield, L., Rao, R., Barrera, L. N., & Costello, E. (2018). Development of Novel Diagnostic Pancreatic Tumor Biomarkers. In Pancreatic Cancer (pp. 1241-1272). Springer New York. doi:10.1007/978-1-4939-7193-0_86
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predict survival in pancreatic cancer.
Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., . . . Greenhalf, W. (2018). Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predict survival in pancreatic cancer.. British Journal of Cancer, 118(7), 947-954. doi:10.1038/s41416-018-0004-2
Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives
Molina-Montes, E., Gomez-Rubio, P., Marquez, M., Rava, M., Lohr, M., Michalski, C. W., . . . Investigators, P. S. (2018). Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 47(2), 473-483. doi:10.1093/ije/dyx269
Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer
Bauer, A. S., Nazarov, P. V., Giese, N. A., Beghelli, S., Heller, A., Greenhalf, W., . . . Hoheisel, J. D. (2018). Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer. INTERNATIONAL JOURNAL OF CANCER, 142(5), 1010-1021. doi:10.1002/ijc.31087
Cytoplasmic HuR Status Predicts Disease-Free Survival in Resected Pancreatic Cancer: A Post-Hoc Analysis from the International Multi-Institutional Phase III ESPAC-3 Clinical Trial
Halloran, C. M. (2018). Cytoplasmic HuR Status Predicts Disease-Free Survival in Resected Pancreatic Cancer: A Post-Hoc Analysis from the International Multi-Institutional Phase III ESPAC-3 Clinical Trial. Annals of Surgery, 267(2), 364-369. doi:10.1097/SLA.0000000000002088
A metabolomics-based biomarker signature discriminates pancreatic cancer from chronic pancreatitis
Costello, E. (2018). A metabolomics-based biomarker signature discriminates pancreatic cancer from chronic pancreatitis. GUT, 67(1), 2-+. doi:10.1136/gutjnl-2016-313665
2017
GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer
Martinelli, P., Pau, E. C. D. S., Cox, T., Sainz, B., Dusetti, N., Greenhalf, W., . . . Real, F. X. (2017). GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut, 66(9), 1665-1676. doi:10.1136/gutjnl-2015-311256
Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium
Campa, D., Obazee, O., Pastore, M., Panzuto, F., Lico, V., Greenhalf, W., . . . Canzian, F. (2017). Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 26(8), 1349-1351. doi:10.1158/1055-9965.EPI-17-0075
A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk
Gomez-Rubio, P., Rosato, V., Marquez, M., Bosetti, C., Molina-Montes, E., Rava, M., . . . Malats, N. (2017). A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. ANNALS OF ONCOLOGY, 28(7), 1618-1624. doi:10.1093/annonc/mdx167
Two contrasting gemcitabine resistance mechanisms involving ribonucleotide reductase and cyclin D1b
Mann, K., Chatzipavli, V., Neoptolemos, J., Costello-Goldring, E., Ghaneh, P., & Greenhalf, W. (2017). Two contrasting gemcitabine resistance mechanisms involving ribonucleotide reductase and cyclin D1b. Pancreatology, 17(3), S43. doi:10.1016/j.pan.2017.05.135
Designing a bio-inspired biomimetic <i>in vitro</i> system for the optimization of <i>ex vivo</i> studies of pancreatic cancer
Totti, S., Vernardis, S. I., Meira, L., Perez-Mancere, P. A., Costello, E., Greenhalf, W., . . . Velliou, E. G. (2017). Designing a bio-inspired biomimetic <i>in vitro</i> system for the optimization of <i>ex vivo</i> studies of pancreatic cancer. DRUG DISCOVERY TODAY, 22(4), 690-701. Retrieved from https://www.webofscience.com/
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
Middleton, G., Palmer, D. H., Greenhalf, W., Ghaneh, P., Jackson, R., Cox, T., . . . Neoptolemos, J. P. (2017). Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. The Lancet Oncology, 18(4), 486-499. doi:10.1016/S1470-2045(17)30084-0
Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways
Brandi, J., Dando, I., Dalla Pozza, E., Biondani, G., Jenkins, R., Elliott, V., . . . Palmieri, M. (2017). Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways. JOURNAL OF PROTEOMICS, 150, 310-322. doi:10.1016/j.jprot.2016.10.002
Reduced risk of pancreatic cancer associated with asthma and nasal allergies
Gomez-Rubio, P., Zock, J. -P., Rava, M., Marquez, M., Sharp, L., Hidalgo, M., . . . Investigators, P. S. (2017). Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Gut, 66(2), 314-322. doi:10.1136/gutjnl-2015-310442
2016
Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice
Jandaghi, P., Najafabadi, H. S., Bauer, A. S., Papadakis, A. I., Fassan, M., Hall, A., . . . Hoheisel, J. D. (2016). Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. Gastroenterology, 151(6), 1218-1231. doi:10.1053/j.gastro.2016.08.040
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
Connor, A. A., Denroche, R. E., Jang, G. H., Timms, L., Kalimuthu, S. N., Selander, I., . . . Gallinger, S. (2016). Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.. JAMA oncology, 3(6), 774-783. doi:10.1001/jamaoncol.2016.3916
Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21
Zhang, M., Wang, Z., Obazee, O., Jia, J., Childs, E. J., Hoskins, J., . . . Amundadottir, L. T. (2016). Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. ONCOTARGET, 7(41), 66328-66343. doi:10.18632/oncotarget.11041
The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer
Kleeff, J., Costello, E., Jackson, R., Halloran, C., Greenhalf, W., Ghaneh, P., . . . Neoptolemos, J. P. (2016). The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. BRITISH JOURNAL OF CANCER, 115(7), 887-894. doi:10.1038/bjc.2016.277
Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk
Campa, D., Pastore, M., Gentiluomo, M., Talar-Wojnarowska, R., Kupcinskas, J., Malecka-Panas, E., . . . Canzian, F. (2016). Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. ONCOTARGET, 7(35), 57011-57020. doi:10.18632/oncotarget.10935
Early epigenetic downregulation of microRNA-192 expression promotes pancreatic cancer progression
Botla, S. K., Savant, S., Jandaghi, P., Bauer, A. S., Mucke, O., Moskalev, E. A., . . . Hoheisel, J. D. (2016). Early epigenetic downregulation of microRNA-192 expression promotes pancreatic cancer progression. Cancer Research, 76(14), 4149-4159. doi:10.1158/0008-5472.CAN-15-0390
miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer
Muehlberg, L., Kuehnemuth, B., Costello, E., Shaw, V., Sipos, B., Huber, M., . . . Michl, P. (2016). miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer. ONCOIMMUNOLOGY, 5(6). doi:10.1080/2162402X.2016.1160181
Activated Schwann cells in pancreatic cancer are linked to analgesia via suppression of spinal astroglia and microglia
Demir, I. E., Tieftrunk, E., Schorn, S., Saricaoglu, O. C., Pfitzinger, P. L., Teller, S., . . . Ceyhan, G. O. (2016). Activated Schwann cells in pancreatic cancer are linked to analgesia via suppression of spinal astroglia and microglia. GUT, 65(6), 1001-1014. doi:10.1136/gutjnl-2015-309784
Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitus
Jenkinson, C., Elliott, V., Evans, A., Oldfield, L., Jenkins, R., O'Brien, D., . . . Costello-Goldring, E. (2016). Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitus. Clinical Cancer Research, 22(7), 1734-1743. doi:10.1158/1078-0432.ccr-15-0879
Secretome protein signature of human pancreatic cancer stem-like cells
Brandi, J., Dalla Pozza, E., Dando, I., Biondani, G., Robotti, E., Jenkins, R., . . . Cecconi, D. (2016). Secretome protein signature of human pancreatic cancer stem-like cells. JOURNAL OF PROTEOMICS, 136, 1-12. doi:10.1016/j.jprot.2016.01.017
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
Middleton, G., Greenhalf, W., Costello, E., Shaw, V., Cox, T., Ghaneh, P., . . . Neoptolemos, J. P. (2016). Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. British Journal of Cancer, 114, 510-518. doi:10.1038/bjc.2015.468
Choline Kinase Alpha (CHK alpha) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors
Mazarico, J. M., Sanchez-Arevalo Lobo, V. J., Favicchio, R., Greenhalf, W., Costello, E., Carrillo-de Santa Pau, E., . . . Real, F. X. (2016). Choline Kinase Alpha (CHK alpha) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. MOLECULAR CANCER THERAPEUTICS, 15(2), 323-333. doi:10.1158/1535-7163.MCT-15-0214
From mice to men: Murine models of colorectal cancer for use in translational research
Evans, J. P., Sutton, P. A., Winiarski, B. K., Fenwick, S. W., Malik, H. Z., Vimalachandran, D., . . . Kitteringham, N. R. (2016). From mice to men: Murine models of colorectal cancer for use in translational research. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 98, 94-105. doi:10.1016/j.critrevonc.2015.10.009
UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis
Abu-Alainin, W., Gana, T., Liloglou, L., Olayanju, A., Barrera Briceno, L., Ferguson, R., . . . Costello-Goldring, E. (2016). UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis. Journal of Pathology, 238(3), 423-433. doi:10.1002/path.4665
2015
<i>TERT</i> gene harbors multiple variants associated with pancreatic cancer susceptibility
Campa, D., Rizzato, C., Stolzenberg-Solomon, R., Pacetti, P., Vodicka, P., Cleary, S. P., . . . Canzian, F. (2015). <i>TERT</i> gene harbors multiple variants associated with pancreatic cancer susceptibility. INTERNATIONAL JOURNAL OF CANCER, 137(9), 2175-2183. doi:10.1002/ijc.29590
Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma
Radon, T. P., Massat, N. J., Jones, R., Alrawashdeh, W., Dumartin, L., Ennis, D., . . . Crnogorac-Jurcevic, T. (2015). Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. CLINICAL CANCER RESEARCH, 21(15), 3512-3521. doi:10.1158/1078-0432.CCR-14-2467
Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms
Cioffi, M., Trabulo, S., Hidalgo, M., Costello, E., Greenhalf, W., Erkan, M., . . . Heeschen, C. (2015). Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Clinical Cancer Research, 21(10), 2325-2337. doi:10.1158/1078-0432.CCR-14-1399
Biomarkers for early diagnosis of pancreatic cancer
Jenkinson, C., Earl, J., Ghaneh, P., Halloran, C., Carrato, A., Greenhalf, B., . . . Costello-Goldring, E. (2015). Biomarkers for early diagnosis of pancreatic cancer. Expert Review of Gastroenterology & Hepatology, 9(03), 305-315. doi:10.1586/17474124.2015.965145
Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection
O'Brien, D. P., Sandanayake, N. S., Jenkinson, C., Gentry-Maharaj, A., Apostolidou, S., Fourkala, E. -O., . . . Timms, J. F. (2015). Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection. Clinical Cancer Research, 21(3), 622-631. doi:10.1158/1078-0432.CCR-14-0365
Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer
Jenkinson, C., Elliott, V., Menon, U., Apostolidou, S., Fourkala, O. E., Gentry-Maharaj, A., . . . Costello, E. (2015). Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. JOURNAL OF PROTEOMICS, 113, 400-402. doi:10.1016/j.jprot.2014.10.001
Pancreatic Mass in a Young <i>CFTR</i> Carrier With a Heterozygous p.R117H <i>CFTR</i> Gene Mutation and Homozygous 7T
Hanna, T., Abdul-Rahman, Z., Greenhalf, W., Costello, E., & Neoptolemos, J. P. (2015). Pancreatic Mass in a Young <i>CFTR</i> Carrier With a Heterozygous p.R117H <i>CFTR</i> Gene Mutation and Homozygous 7T. PANCREAS, 44(2), 343-345. doi:10.1097/MPA.0000000000000244
2014
Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer
Wolpin, B. M., Rizzato, C., Kraft, P., Kooperberg, C., Petersen, G. M., Wang, Z., . . . Amundadottir, L. T. (2014). Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. NATURE GENETICS, 46(9), 994-1000. doi:10.1038/ng.3052
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Middleton, G., Silcocks, P., Cox, T. F., Valle, J., Wadsley, J., Propper, D., . . . Neoptolemos, J. P. (2014). Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. The Lancet Oncology, 15(8), 829-840. doi:10.1016/S1470-2045(14)70236-0
Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
Shaw, V. E., Lane, B., Jenkinson, C., Cox, T., Greenhalf, W., Halloran, C. M., . . . Costello, E. (2014). Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.. Molecular cancer, 13, 114. doi:10.1186/1476-4598-13-114
Serum cytokine biomarker panels for discriminating Pancreatic Cancer from Benign Pancreatic Disease
Shaw, V. E., Lane, B., Jenkinson, C., Cox, T. F., Greenhalf, W., Halloran, C. M., . . . Costello, E. (2014). Serum cytokine biomarker panels for discriminating Pancreatic Cancer from Benign Pancreatic Disease. Molecular Cancer, 13. Retrieved from https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-13-114
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., . . . Büchler, M. W. (2014). Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.. Journal of the National Cancer Institute, 106(1). doi:10.1093/jnci/djt347
2013
cAMP inhibits migration, ruffling and paxillin accumulation in focal adhesions of pancreatic ductal adenocarcinoma cells: Effects of PKA and EPAC
Burdyga, A., Conant, A., Haynes, L., Zhang, J., Jalink, K., Sutton, R., . . . Tepikin, A. (2013). cAMP inhibits migration, ruffling and paxillin accumulation in focal adhesions of pancreatic ductal adenocarcinoma cells: Effects of PKA and EPAC. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1833(12), 2664-2672. doi:10.1016/j.bbamcr.2013.06.011
The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer
Thornton, M., Aslam, M. A., Tweedle, E. M., Ang, C., Campbell, F., Jackson, R., . . . Boyd, M. T. (2013). The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. International Journal of Cancer, 133(6), 1408-1418. doi:10.1002/ijc.28137
The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer
Thornton, M., Aslam, M. A., Tweedle, E. M., Ang, C., Campbell, F., Jackson, R., . . . Boyd, M. T. (2013). The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. INTERNATIONAL JOURNAL OF CANCER, 133(6), 1408-1418. doi:10.1002/ijc.28137
iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance
Tonack, S., Jenkinson, C., Cox, T., Elliott, V., Jenkins, R. E., Kitteringham, N. R., . . . Costello, E. (2013). iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. BRITISH JOURNAL OF CANCER, 108(9), 1846-1853. doi:10.1038/bjc.2013.150
iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance
Tonack, S., Jenkinson, C., Cox, T., Elliott, V., Jenkins, R. E., Kitteringham, N. R., . . . Costello, E. (2013). iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. British Journal of Cancer, 108(9), 1846-1853. doi:10.1038/bjc.2013.150
EU Pancreas: An Integrated European Platform for Pancreas Cancer Research - from Basic Science to Clinical and Public Health Interventions for a Rare Disease
Milne, R., La Vecchia, C., Van Steen, K., Hahn, S., Buchholz, M., Costello, E., . . . Malats, N. (2013). EU Pancreas: An Integrated European Platform for Pancreas Cancer Research - from Basic Science to Clinical and Public Health Interventions for a Rare Disease. PUBLIC HEALTH GENOMICS, 16(6), 305-312. doi:10.1159/000355937
Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival
Rachakonda, P. S., Bauer, A. S., Xie, H., Campa, D., Rizzato, C., Canzian, F., . . . Kumar, R. (2013). Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival. PLOS ONE, 8(4). doi:10.1371/journal.pone.0060870
Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium
Campa, D., Rizzato, C., Capurso, G., Giese, N., Funel, N., Greenhalf, W., . . . Canzian, F. (2013). Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. Digestive and Liver Disease, 45(2), 95-99. doi:10.1016/j.dld.2012.09.014
Lack of Replication of Seven Pancreatic Cancer Susceptibility Loci Identified in Two Asian Populations
Campa, D., Rizzato, C., Bauer, A. S., Werner, J., Capurso, G., Costello, E., . . . Canzian, F. (2013). Lack of Replication of Seven Pancreatic Cancer Susceptibility Loci Identified in Two Asian Populations. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 22(2), 320-323. doi:10.1158/1055-9965.EPI-12-1182
Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium
Campa, D., Rizzato, C., Capurso, G., Giese, N., Funel, N., Greenhalf, W., . . . Canzian, F. (2013). Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. DIGESTIVE AND LIVER DISEASE, 45(2), 95-99. doi:10.1016/j.dld.2012.09.014
Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival
Rachakonda, P. S., Bauer, A. S., Xie, H., Campa, D., Rizzato, C., Canzian, F., . . . Kumar, R. (n.d.). Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival. PLoS ONE, 8(4), e60870. doi:10.1371/journal.pone.0060870
2012
The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion
Evans, A., & Costello, E. (2012). The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. FRONTIERS IN PHYSIOLOGY, 3. doi:10.3389/fphys.2012.00270
New biomarkers and targets in pancreatic cancer and their application to treatment
Costello, E., Greenhalf, W., & Neoptolemos, J. P. (2012). New biomarkers and targets in pancreatic cancer and their application to treatment. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 9(8), 435-444. doi:10.1038/nrgastro.2012.119
Nanotechnology advances in upper gastrointestinal, liver and pancreatic cancer
Sykes, P. D., Neoptolemos, J. P., Costello, E., & Halloran, C. M. (2012). Nanotechnology advances in upper gastrointestinal, liver and pancreatic cancer. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 6(3), 343-356. doi:10.1586/EGH.12.13
Diagnosis of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis by Measurement of microRNA Abundance in Blood and Tissue
Bauer, A. S., Keller, A., Costello, E., Greenhalf, W., Bier, M., Borries, A., . . . Hoheisel, J. D. (2012). Diagnosis of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis by Measurement of microRNA Abundance in Blood and Tissue. PLOS ONE, 7(4). doi:10.1371/journal.pone.0034151
Pancreatic Cancer Biomarker Panel
Costello-Goldring, E. (2012). Pancreatic Cancer Biomarker Panel.
2011
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer, 10(1). doi:10.1186/1476-4598-10-37
Pancreatic Cancer Susceptibility Loci and Their Role in Survival
Rizzato, C., Campa, D., Giese, N., Werner, J., Rachakonda, P. S., Kumar, R., . . . Canzian, F. (2011). Pancreatic Cancer Susceptibility Loci and Their Role in Survival. PLOS ONE, 6(11). doi:10.1371/journal.pone.0027921
Circulating MicroRNAs as Potential Markers of Human Drug-Induced Liver Injury
Lewis, P. J. S., Dear, J., Platt, V., Simpson, K. J., Craig, D. G. N., Antoine, D. J., . . . Park, B. K. (2011). Circulating MicroRNAs as Potential Markers of Human Drug-Induced Liver Injury. HEPATOLOGY, 54(5), 1767-1776. doi:10.1002/hep.24538
Multifunctional Fe<sub>3</sub>O<sub>4</sub> nanoparticles for targeted bi-modal imaging of pancreatic cancer
Olariu, C. I., Yiu, H. H. P., Bouffier, L., Nedjadi, T., Costello, E., Williams, S. R., . . . Rosseinsky, M. J. (2011). Multifunctional Fe<sub>3</sub>O<sub>4</sub> nanoparticles for targeted bi-modal imaging of pancreatic cancer. JOURNAL OF MATERIALS CHEMISTRY, 21(34), 12650-12659. doi:10.1039/c1jm11370d
Enhancing the translation of cancer biomarkers
Costello, E., & Neoptolemos, J. (2011). Enhancing the translation of cancer biomarkers. BRITISH JOURNAL OF SURGERY, 98(8), 1039-1040. doi:10.1002/bjs.7556
Tetracycline-inducible protein expression in pancreatic cancer cells: Effects of CapG overexpression
Tonack, S., Patel, S., Jalali, M., Nedjadi, T., Jenkins, R. E., Goldring, C., . . . Costello, E. (2011). Tetracycline-inducible protein expression in pancreatic cancer cells: Effects of CapG overexpression. WORLD JOURNAL OF GASTROENTEROLOGY, 17(15), 1947-1960. doi:10.3748/wjg.v17.i15.1947
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. MOLECULAR CANCER, 10. doi:10.1186/1476-4598-10-37
PANCREATIC CANCER IN 2010 New insights for early intervention and detection
Costello, E., & Neoptolemos, J. P. (2011). PANCREATIC CANCER IN 2010 New insights for early intervention and detection. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 8(2), 71-73. doi:10.1038/nrgastro.2010.214
Circulating microRNAs as potential markers of human drug-induced liver injury
Lewis Starkey, P. J., Dear, J., Platt, V., Simpson, K. J., Craig, D. G., Antoine, D. J., . . . Park, B. K. (2011). Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology, 1767-1776.
Circulating microRNAs as potential markers of human drug-induced liver injury
Starkey Lewis, P. J., Dear, J., Platt, V., Simpson, K. J., Craig, D. G., Antoine, D. J., . . . Park, B. K. (2011). Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology.
Combined LC-MS/MS and iTRAQ analysis of serum and pancreatic juice for the detection of biomarkers for pancreatic cancer: Influence of biliary obstruction
Tonack, S., Jenkinson, C., Elliot, V., Dajani, K., Jenkins, R. E., Kitteringham, N. R., . . . Costello, E. (2011). Combined LC-MS/MS and iTRAQ analysis of serum and pancreatic juice for the detection of biomarkers for pancreatic cancer: Influence of biliary obstruction. Pancreas, 40, 1358.
Multifunctional Fe3O4 nanoparticles for targeted bi-modal imaging of pancreatic cancer
Olariu, C. I., Yiu, H. H. P., Bouffier, L., Nedjadi, T., Costello, E., Williams, S. R., . . . Rosseinsky, M. J. (2011). Multifunctional Fe3O4 nanoparticles for targeted bi-modal imaging of pancreatic cancer. J. Mater. Chem.
Nrf2 is over-expressed in pancreatic cancer: implications for cell proliferation and therapy
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is over-expressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer, 10, 37.
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.. Mol Cancer, 10(1), 37.
Pancreatic cancer in 2010
Costello, E., & Neoptolemos, J. P. (2011). Pancreatic cancer in 2010. Nat Rev Gastroenterol Hepatol., 8(2), 71-73.
2010
Proteomic Analysis of Blood and Pancreatic Juice
Aspinall-O'Dea, M., Neoptolemos, J., & Costello, E. (2010). Proteomic Analysis of Blood and Pancreatic Juice. In DRUG DISCOVERY IN PANCREATIC CANCER: MODELS AND TECHNIQUES (pp. 223-241). doi:10.1007/978-1-4419-1160-5_12
Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer
Tweedle, E. M., Khattak, I., Ang, C. W., Nedjadi, T., Jenkins, R., Park, B. K., . . . Costello, E. (2010). Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. GUT, 59(11), 1501-1510. doi:10.1136/gut.2009.196626
Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer
Shaw, V. E., Naisbitt, D. J., Costello, E., Greenhalf, W., Park, B. K., Neoptolemos, J. P., & Middleton, G. W. (2010). Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. EXPERT REVIEW OF VACCINES, 9(9), 1007-1016. doi:10.1586/ERV.10.92
Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells
Ang, C. W., Nedjadi, T., Sheikh, A. A., Tweedle, E. M., Tonack, S., Honap, S., . . . Costello, E. (2010). Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. CARCINOGENESIS, 31(9), 1541-1551. doi:10.1093/carcin/bgq137
Dual-color Proteomic Profiling of Complex Samples with a Microarray of 810 Cancer-related Antibodies
Schroeder, C., Jacob, A., Tonack, S., Radon, T. P., Sill, M., Zucknick, M., . . . Hoheisel, J. D. (2010). Dual-color Proteomic Profiling of Complex Samples with a Microarray of 810 Cancer-related Antibodies. MOLECULAR & CELLULAR PROTEOMICS, 9(6), 1271-1280. doi:10.1074/mcp.M900419-MCP200
Analysis of Serum Proteins by LC-MS/MS
Tonack, S., Neoptolemos, J. P., & Costello, E. (2010). Analysis of Serum Proteins by LC-MS/MS. LC-MS/MS IN PROTEOMICS: METHODS AND APPLICATIONS, 658, 281-291. doi:10.1007/978-1-60761-780-8_17
Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies
Schröder, C., Jacob, A., Tonack, S., Radon, T. P., Sill, M., Zucknick, M., . . . Hoheisel, J. D. (2010). Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies. Molecular and Cellular Proteomics, 9(6), 1501-1510.
Multifunctional nanoparticles for healthcare applications
Olariu, C. I., Yiu, H. P. P., Bouffier, L., Nedjadi, T., Costello, E., Halloran, C. M., & Rosseinsky, M. J. (2010). Multifunctional nanoparticles for healthcare applications. European Cells and Materials, 20(SUPPL.3), 192.
2009
A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ
Tonack, S., Aspinall-O'Dea, M., Jenkins, R. E., Elliot, V., Murray, S., Lane, C. S., . . . Costello, E. (2009). A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. JOURNAL OF PROTEOMICS, 73(2), 352-356. doi:10.1016/j.jprot.2009.07.009
S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility
Nedjadi, T., Kitteringham, N., Campbell, F., Jenkins, R. E., Park, B. K., Navarro, P., . . . Costello, E. (2009). S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. BRITISH JOURNAL OF CANCER, 101(7), 1145-1154. doi:10.1038/sj.bjc.6605289
Confounding Effect of Obstructive Jaundice in the Interpretation of Proteomic Plasma Profiling Data for Pancreatic Cancer
Yan, L., Tonack, S., Smith, R., Dodd, S., Jenkins, R. E., Kitteringham, N., . . . Costello, E. (2009). Confounding Effect of Obstructive Jaundice in the Interpretation of Proteomic Plasma Profiling Data for Pancreatic Cancer. JOURNAL OF PROTEOME RESEARCH, 8(1), 142-148. doi:10.1021/pr800451h
Pancreatic Cancer: Proteomic Approaches to a Challenging Disease
Tonack, S., Aspinall-O'Dea, M., Neoptolemos, J. P., & Costello, E. (2009). Pancreatic Cancer: Proteomic Approaches to a Challenging Disease. PANCREATOLOGY, 9(5), 567-576. doi:10.1159/000212083
2008
New treatment options for advanced pancreatic cancer.
Middleton, G., Ghaneh, P., Costello, E., Greenhalf, W., & Neoptolemos, J. P. (2008). New treatment options for advanced pancreatic cancer.. Expert review of gastroenterology & hepatology, 2(5), 673-696. doi:10.1586/17474124.2.5.673
Biology and management of pancreatic cancer
Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2007). Biology and management of pancreatic cancer. GUT, 56(8), 1134-1152. doi:10.1136/gut.2006.103333
Biology and management of pancreatic cancer.
Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2008). Biology and management of pancreatic cancer.. Postgraduate medical journal, 84(995), 478-497. doi:10.1136/gut.2006.103333
Molecular Biological Understanding of Development of Pancreatic Cancer
Costello, E. (2008). Molecular Biological Understanding of Development of Pancreatic Cancer. In Unknown Book (pp. 583-590). Wiley. doi:10.1002/9781444300123.ch58
2007
The pancreatic cancer proteome - recent advances and future promise
Aspinall-O'Dea, M., & Costello, E. (2007). The pancreatic cancer proteome - recent advances and future promise. PROTEOMICS CLINICAL APPLICATIONS, 1(9), 1066-1079. doi:10.1002/prca.200700144
Both HIV- and EIAV-based lentiviral vectors mediate gene delivery to pancreatic cancer cells and human pancreatic primary patient xenografts
Saraga, G., Mafficini, A., Ghaneh, P., Sorio, C., & Costello, E. (2007). Both HIV- and EIAV-based lentiviral vectors mediate gene delivery to pancreatic cancer cells and human pancreatic primary patient xenografts. CANCER GENE THERAPY, 14(9), 781-790. doi:10.1038/sj.cgt.7701066
The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells
Sheikh, A. A., Vimalachandran, D., Thompson, C. C., Jenkins, R. E., Nedjadi, T., Shekouh, A., . . . Costello, E. (2007). The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. PROTEOMICS, 7(11), 1929-1940. doi:10.1002/pmic.200700072
Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility
Thompson, C. C., Ashcroft, F. J., Patel, S., Saraga, G., Vimalachandran, D., Prime, W., . . . Costello, E. (2007). Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. GUT, 56(1), 95-106. doi:10.1136/gut.2005.083691
2006
Molecular-biological understanding of the development of pancreatic cancer
Costello, E. (2006). Molecular-biological understanding of the development of pancreatic cancer. In H. Beger, M. Büchler, & R. Kozarek (Eds.), The Pancreas: A Clinical and Surgical Text, 2e (pp. 6). Oxford: Blackwell Publishing Ltd.
Tetracycline-inducible pancreatic cancer cell lines
Patel, S. I., Bier, M., Goldring, C. E. P., Hillen, W., & Costello, E. (2006). Tetracycline-inducible pancreatic cancer cell lines. PANCREAS, 4(33), 489.
The expression of S100A8 in tumour-associated monocytes is associated with the Smad4 status of pancreatic and colorectal cancer
Sheikh, A. A., Vimalachandran, D., Tweedle, E. M., Prime, W., Campbell, F., Dodson, A., . . . Costello, E. (2006). The expression of S100A8 in tumour-associated monocytes is associated with the Smad4 status of pancreatic and colorectal cancer. Pancreas, 4(33), 506.
2005
Trials of gene therapy for pancreatic carcinoma
Halloran, C. M., Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2005). Trials of gene therapy for pancreatic carcinoma. Current Gastroenterology Reports, 7(3), 165-169. doi:10.1007/s11894-005-0028-7
High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients
Vimalachandran, D., Greenhalf, W., Thompson, C., Lüttges, J., Prime, W., Campbell, F., . . . Costello, E. (2005). High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. CANCER RESEARCH, 65(8), 3218-3225. doi:10.1158/0008-5472.CAN-04-4311
Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma
Crnogorac-Jurcevic, T., Gangeswaran, R., Bhakta, V., Capurso, G., Lattimore, S., Akada, M., . . . Lemoine, N. R. (2005). Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. GASTROENTEROLOGY, 129(5), 1454-1463. doi:10.1053/j.gastro.2005.08.012
Proteomic analysis of pancreas samples using two-dimensional electrophoresis combined with mass spectrometry
Shore, S., Vimalachandran, D., Neoptolemos, J. P., & Costello, E. (2005). Proteomic analysis of pancreas samples using two-dimensional electrophoresis combined with mass spectrometry. In T. M. Gress, J. P. Neoptoelmos, & N. R. Lemoine (Eds.), Exocrine pancreas cancer (pp. 244-253). Hannover: Felsenstein CCCP.
Trials of gene therapy for pancreatic carcinoma.
Halloran, C. M., Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2005). Trials of gene therapy for pancreatic carcinoma.. Current gastroenterology reports, 7(3), 165-169. doi:10.1007/s11894-005-0028-7
2004
Proteomic technologies and their application to pancreatic cancer
Vimalachandran, D., & Costello, E. (2004). Proteomic technologies and their application to pancreatic cancer. EXPERT REVIEW OF PROTEOMICS, 1(4), 493-501. doi:10.1586/14789450.1.4.493
Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis
Missiaglia, E., Blaveri, E., Terris, B., Wang, Y. H., Costello, E., Neoptolemos, J. P., . . . Lemoine, N. R. (2004). Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. INTERNATIONAL JOURNAL OF CANCER, 112(1), 100-112. doi:10.1002/ijc.20376
5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16<SUP>INK4A</SUP> greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells
Halloran, C. M., Ghaneh, P., Shore, S., Greenhalf, W., Zumstein, L., Wilson, D., . . . Costello, E. (2004). 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16<SUP>INK4A</SUP> greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. JOURNAL OF GENE MEDICINE, 6(5), 514-525. doi:10.1002/jgm.540
Genetics and prevention of pancreatic cancer.
Vimalachandran, D., Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2004). Genetics and prevention of pancreatic cancer.. Cancer control : journal of the Moffitt Cancer Center, 11(1), 6-14. doi:10.1177/107327480401100102
2003
Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma
Shekouh, A. R., Thompson, C. C., Prime, W., Campbell, F., Hamlett, J., Herrington, C. S., . . . Costello, E. (2003). Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. PROTEOMICS, 3(10), 1988-2001. doi:10.1002/pmic.200300466
Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent
Crnogorac-Jurcevic, T., Missiaglia, E., Blaveri, E., Gangeswaran, R., Jones, M., Terris, B., . . . Lemoine, N. R. (2003). Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. JOURNAL OF PATHOLOGY, 201(1), 63-74. doi:10.1002/path.1418
2002
MCP-1 but not CINC synthesis is increased in rat pancreatic acini in response to cerulein hyperstimulation
Bhatia, M., Brady, M., Kang, Y. K., Costello, E., Newton, D. J., Christmas, S. E., . . . Slavin, J. (2002). MCP-1 but not CINC synthesis is increased in rat pancreatic acini in response to cerulein hyperstimulation. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 282(1), G77-G85. doi:10.1152/ajpgi.00031x.2002
MCP-1 but not CINC synthesis is increased in rat pancreatic acini in response to cerulein hyperstimulation.
Bhatia, M., Brady, M., Kang, Y. K., Costello, E., Newton, D. J., Christmas, S. E., . . . Slavin, J. (2002). MCP-1 but not CINC synthesis is increased in rat pancreatic acini in response to cerulein hyperstimulation.. American journal of physiology. Gastrointestinal and liver physiology, 282(1), G77-G85. doi:10.1152/ajpgi.00031x.2002
2001
Stable transduction with lentiviral vectors and amplification of immature hematopoietic progenitors from cord blood of preterm human fetuses
Luther-Wyrsch, A., Costello, E., Thali, M., Buetti, E., Nissen, C., Surbek, D., . . . Wodnar-Filipowicz, A. (2001). Stable transduction with lentiviral vectors and amplification of immature hematopoietic progenitors from cord blood of preterm human fetuses. HUMAN GENE THERAPY, 12(4), 377-389. doi:10.1089/10430340150504000
Fetal hematopoietic stem cells: In vitro expansion and transduction using lentiviral vectors
Luther-Wyrsch, A., Nissen, C., Surbek, D. V., Holzgreve, W., Costello, E., Thali, M., . . . Wodnar-Filipowicz, A. (2001). Fetal hematopoietic stem cells: In vitro expansion and transduction using lentiviral vectors. STEM CELLS FORM CORD BLOOD, IN UTERO STEM CELL DEVELOPMENT, AND TRANSPLANTATION-INCLUSIVE GENE THERAPY, 33, 123-144. Retrieved from https://www.webofscience.com/
2000
Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors
Costello, E., Munoz, M., Buetti, E., Meylan, P. R. A., Diggelmann, H., & Thali, M. (2000). Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. GENE THERAPY, 7(7), 596-604. doi:10.1038/sj.gt.3301135
Gene therapy for pancreatic cancer - current and prospective strategies
Halloran, C. M., Ghaneh, P., Neoptolemos, J. P., & Costello, E. (2000). Gene therapy for pancreatic cancer - current and prospective strategies. SURGICAL ONCOLOGY-OXFORD, 9(4), 181-191. doi:10.1016/S0960-7404(01)00011-1
1997
High mobility group chromosomal protein 1 binds to the adeno-associated virus replication protein (Rep) and promotes Rep-mediated site-specific cleavage of DNA, ATPase activity and transcriptional repression
Costello, E., Saudan, P., Winocour, E., Pizer, L., & Beard, P. (1997). High mobility group chromosomal protein 1 binds to the adeno-associated virus replication protein (Rep) and promotes Rep-mediated site-specific cleavage of DNA, ATPase activity and transcriptional repression. EMBO JOURNAL, 16(19), 5943-5954. doi:10.1093/emboj/16.19.5943
The minute virus of mice (MVM) nonstructural protein NS1 induces nicking of MVM DNA at a unique site of the right-end telomere in both hairpin and duplex conformations in vitro
Willwand, K., Baldauf, A. Q., Deleu, L., Mumtsidu, E., Costello, E., Beard, P., & Rommelaere, J. (1997). The minute virus of mice (MVM) nonstructural protein NS1 induces nicking of MVM DNA at a unique site of the right-end telomere in both hairpin and duplex conformations in vitro. JOURNAL OF GENERAL VIROLOGY, 78, 2647-2655. doi:10.1099/0022-1317-78-10-2647
1995
THE MISMATCHED NUCLEOTIDES IN THE 5'-TERMINAL HAIRPIN OF MINUTE VIRUS OF MICE ARE REQUIRED FOR EFFICIENT VIRAL-DNA REPLICATION
COSTELLO, E., SAHLI, R., HIRT, B., & BEARD, P. (1995). THE MISMATCHED NUCLEOTIDES IN THE 5'-TERMINAL HAIRPIN OF MINUTE VIRUS OF MICE ARE REQUIRED FOR EFFICIENT VIRAL-DNA REPLICATION. JOURNAL OF VIROLOGY, 69(12), 7489-7496. doi:10.1128/JVI.69.12.7489-7496.1995
1994
PROTEIN KINASE-A AND AP-1 (C-FOS/JUND) ARE INDUCED DURING APOPTOSIS OF MOUSE MAMMARY EPITHELIAL-CELLS
MARTI, A., JEHN, B., COSTELLO, E., KEON, N., KE, G., MARTIN, F., & JAGGI, R. (1994). PROTEIN KINASE-A AND AP-1 (C-FOS/JUND) ARE INDUCED DURING APOPTOSIS OF MOUSE MAMMARY EPITHELIAL-CELLS. ONCOGENE, 9(4), 1213-1223. Retrieved from https://www.webofscience.com/
1992
OVEREXPRESSION OF MOS, RAS, SRC, AND FOS INHIBITS MOUSE MAMMARY EPITHELIAL-CELL DIFFERENTIATION
JEHN, B., COSTELLO, E., MARTI, A., KEON, N., DEANE, R., LI, F., . . . JAGGI, R. (1992). OVEREXPRESSION OF MOS, RAS, SRC, AND FOS INHIBITS MOUSE MAMMARY EPITHELIAL-CELL DIFFERENTIATION. MOLECULAR AND CELLULAR BIOLOGY, 12(9), 3890-3902. doi:10.1128/MCB.12.9.3890